Hyperion Therapeutics IPO Criticized for Poor Corporate Governance by UNITEHERE
NEW YORK--(BUSINESS WIRE)--UNITEHERE Research criticized Hyperion Therapeutics (NASDAQ: HPTX), which is undertaking an initial public offering, for weak corporate governance and a plethora of anti-takeover provisions which could disadvantage new investors.